Search Results for “Sanofi” – Page 7 – media

Philippines halts sale of Sanofi’s dengue vaccine

The Philippines has suspended the sale and distribution of Sanofi’s dengue vaccine, authorities said on Tuesday, after the French pharmaceutical giant last week warned it could worsen symptoms for people who had not previously been infected.
- Source: Thenews
- 759
- December 12, 2017
Dengvaxia vaccine Sanofi’s dengue vaccine
Sanofi Taps into Berg’s AI Platform for Developing Better Flu Vaccine

Machine learning technologies have already made huge strides in supporting the efforts of pharmaceutical companies in developing personalized medicines and novel biomarkers. This has been found to be helpful, notably for understanding the efficacy of prophylactic vaccines used for combating infectious diseases.
- Source: researchmoz.us
- 640
- November 8, 2017
Artificial Intelligence Market Views vaccine
Watch out Sanofi–Takeda’s new data on dengue vaccine is good news for PhIII trial

Prospects for Takeda’s dengue vaccine just turned brighter following fresh data from the company’s Phase II trial. For Takeda, the data is likely welcome considering the company already has a massive pivotal trial underway for the vaccine. For competitor Sanofi … perhaps not so welcome.
- Source: endpts
- 944
- November 7, 2017
antibody dengue Phase vaccine
Sanofi, Regeneron’s biologic shines again in asthma trial

Regeneron and Sanofi have unveiled positive new data from a late-stage trial investigating the biologic dupilumab in adults and adolescents 12 years of age and older with severe, steroid dependent asthma.
- Source: Pharmatimes
- 1,076
- November 3, 2017
asthma Clinical Trial dupilumab
Regeneron (REGN) And Sanofi (SNY) Announce Positive Dupilumab Topline Results From Phase III Trial In Uncontrolled Persistent Asthma

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the pivotal Phase 3 LIBERTY ASTHMA QUEST study of dupilumab in a broad population of patients with uncontrolled, persistent asthma met its two primary endpoints.
- Source: careers.biospace
- 557
- September 12, 2017
asthma Clinical Trials dupilumab Phase
Sanofi wins tentative FDA nod for Admelog insulin lispro injection

Sanofi announced that the U.S. Food and Drug Administration (FDA) granted tentative approval for Admelog® (insulin lispro injection) 100 Units/mL, a rapid-acting human insulin analog. Admelog is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Source: yahoo
- 741
- September 7, 2017
Company Insight diabetes FDA insulin New Approvals
Sanofi, Ablynx sign $2.7bn research, licensing pact

Sanofi has signed a research pact and licensing deal with Ablynx that could bring as much as $2.7 billion euros to the Belgian biotech’s coffers if all targets are met.
- Source: pharmatimes
- 504
- July 21, 2017
Company Insight Market Views Sanofi Ablynx
Sanofi snaps up Protein Sciences for $650 million

Sanofi is to buy private US vaccines biotech Protein Sciences in a deal valued at up to $750 million, in a move to bolster its vaccines portfolio.
- Source: pharmatimes
- 457
- July 7, 2017
Company Insight Market Views vaccine
Regeneron’s midlife crisis

Regeneron is a role model for the biotech community. No biotech company wants to be Regeneron. “Becoming China’s Regeneron” is the slogan of many domestic biotechs. However, such a Regeneron cannot escape its midlife crisis. The attack of opponents, the victory of Eylea generic drugs, and the successive blows of dual-antibodies have put Regeneron in an extremely delicate stage. On the one hand, with two blockbuster drugs, Regeneron has completed the transformation from biotech to big pharma. In the first half of the year, its stock price continued to rise, successfully breaking through the $100 billion threshold, and its market value reached $133.2 billion. On the other hand, although the market believes in Regeneron’s R&D and platform technology capabilities, how can a new billion-dollar blockbuster drug be so easy? And Regeneron’s highly anticipated oncology business is not as glamorous as autoimmunity and ophthalmology, and its progress is also lackluster. So ...
- Source: drugdu
- 41
- November 22, 2024
Uncovering the truth of AbbVie’s $8.7 billion lesson

M&A is a metaphysics, with heaven on one side and hell on the other, tempting prominent names to enter. The latest to enter “hell” is AbbVie. On November 11, AbbVie announced that emraclidine, the “ace project” acquired by acquiring Cerevel for $8.7 billion at the end of last year, failed to reach the expected endpoint in two Phase II studies for schizophrenia, which cast a shadow on its future. As soon as the news came out, AbbVie’s stock price plummeted 12.57%, and its market value evaporated by more than $40 billion overnight. Once, this merger and acquisition was a “model” in the industry. From the first acquisition invitation to the final acquisition of Cerevil, AbbVie took less than two months. Fast, accurate, and ruthless, it foreshadowed AbbVie’s determination to deal with the patent cliff. But now, everything is coming to nothing. This once again allows us to see the “variables” ...
- Source: drugdu
- 56
- November 15, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.